HD Medical at CES Unveils HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness
11.1.2021 16:05:00 EET | Business Wire | Press release
At CES’21, HD Medical Inc. today introduces HealthyU™, an intelligent remote patient monitoring device, in response to the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005444/en/
HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness. HD Medical Inc.'s HealthyU™ is an at-home monitoring device that addresses the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond. (Graphic: Business Wire)
HealthyU™ is the first home device to provide:
- 7-lead ECG (without wires)
- Heart Sounds with Murmur Analysis
- Lung Sounds
- Heart Rate
- Pulse Oximetry (SpO2 / blood oxygen saturation)
- Temperature
- Respiratory Rate
- Cuffless Blood Pressure Trend
The Future of Telehealth, Home Monitoring, and Wellness
As the medical community seek new ways to deliver care, HealthyU™ takes multiple complex healthcare devices and turns them into one easy-to-use device for the patient and the provider to connect via a simple HD App and HD Cloud Platform for Intelligent Insights, or also with any video conferencing and screen sharing tool for Remote Consultation.
Providers can listen live to the heart and lung sounds using HD Steth™, HD Medical’s flagship intelligent stethoscope technology, cleared by FDA in July 2020 for Electronic Stethoscope, Phonocardiograph and Electrocardiograph.
Created with and available first to those with cardiac care and monitoring needs, HealthyU™ is available to clinical partners for research and corporate wellness partners seeking employee wellness offerings of this caliber, as well as for Telehealth pilot programs under IRB Protocol in accordance with FDA Regulations. HD Medical will be seeking Emergency Use Authorization from the FDA to make available in the U.S. and enable fully informed at-home doctor-patient visits during the pandemic and beyond.
HD Medical at CES Unveils HealthyU
“I’ve been treating patients remotely for nearly a year now and the pandemic has severely limited my ability to understand my patient’s condition. As we move forward, telehealth represents a paradigm shift in healthcare delivery during the pandemic and beyond. HealthyU will play a critical role and promises to not only save lives but also improve the quality of life for all patients,” said Dr. Nelson B. Schiller, MD, FACC, FRCP, Professor of Medicine & Anesthesia, UCSF.
"HealthyU is one of those rare medical devices that is truly a game changer in patient care. Being so user friendly and clinically sound, this device can be used in many different clinical scenarios and can truly be a lifesaver for multitudes of patients, who have the possibility of obtaining care while at home," said Dr. Shaun Setty, MD of The Larry and Helen Hoag Endowed Chair of Pediatric Cardiovascular Surgery in Los Angeles, CA.
“2020 has put greater emphasis on the need to advance remote patient monitoring technology, which is why we have prioritized bringing integrated sensors and intelligent insights into the home making it easy for patients to use and viable for providers to leverage during care,” said Arvind Thiagarajan, founder and CEO of HD Medical. “HealthyU™ performs wireless ECG outside of the hospital while incorporating auscultation and other important vitals. By simplifying the remote monitoring process, we’ve ensured this technology can be leveraged by anyone that needs it.”
HealthyU is currently intended for investigational use only, not for sale in the United States until after FDA clearance. HD Medical expects that HealthyU will be available for sale in the US by the third quarter of 2021, subject to FDA clearance process, which is being undertaken expeditiously. In the meantime, HealthyU will be available to clinical partners for research and corporate wellness programs, as well as telehealth pilot programs under the IRB protocol in accordance with FDA regulations.
To become a HealthyU™ partner, email info@hdmedicalgroup.com.
About HD Medical, Inc.
HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299). The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions through channel partners. Visit www.HealthyU.ai and www.hdmedicalgroup.com.
Note to editors: HealthyU, HD Steth, HD App, and HD Cloud Platform are registered trademarks of HD Medical, Inc. All other product, service or organization names remain the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005444/en/
Contact information
Kristi Furrer
HD Medical, Inc.
kristi@hdmedicalgroup.com
408-908-8900
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
